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The effects of 5-fluorouracil and interferon-a on early healing of
experimental intestinal anastomoses
JWD de Waard*, T Wobbes, BM de Man, CJ van der Linden and T Hendriks
Department ofSurgery, University Hospital Nijmegen, Nijmegen, The Netherlands.
Summary The continuing search for effective adjuvant therapy after resection of intestinal malignancies has
prompted a growing interest in both immediate post-operative regional chemotherapy and the combination of
5-fluorouracil (5-FU) and interferon-a as drugs of choice. We have compared the effects of both compounds,
alone and together, on early healing of intestinal anastomoses. Four groups (n=26 each) of rats underwent
resection and anastomosis of both ileum and colon: a control group and three groups receiving intraperitoneal
5-FU, interferon-ac or both on the day of surgery and the next 2 days. Animals were killed 3 or 7 days (n= 10
each) after operation in order to measure anastomotic strength and hydroxyproline content. The remaining six
animals in each group were used to study anastomotic collagen synthetic capacity at day 3. Three days after
operation, ileal anastomotic bursting pressure was lowered by 37% in the 5-FU/interferon-a group
(P=0.0104). At day 7, anastomotic breaking strength was reduced significantly in ileum (P=0.0221) and
colon (P=0.0054) ofthe 5-FU/interferon-a group and in colon ofthe interferon-a group (P=0.0221). Collagen
synthetic capacity was strongly suppressed by 5-FU but not by interferon-ac. However, no differences in
anastomotic hydroxyproline content were observed between groups at both days 3 and 7. Thus, post-operative
use of interferon-a, in particular in combination with 5-FU, may be detrimental to anastomotic repair in the
intestine.
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Despite the high resectability rate and general improvement
in surgical therapy, nearly half of all patients with colorectal
cancer will eventually die from recurrent disease. Candidates
for post-operative adjuvant therapy are patients at risk for
disease relapse, as judged by clinical evaluation, surgical
examination and pathological examination of resection
specimens. In general, safe and effective adjuvant therapy
would be highly desirable in patients with Dukes' stage B2
and C colon carcinoma, which constitute 60-70% of the
population presenting with colorectal cancer.
Over the last three decades numerous studies have shown
little or no survival benefit, although small but significant
clinical improvement, from post-operative chemotherapy
using 5-fluorouracil (5-FU) as the primary agent (Kemeny
et al., 1993; Moertel, 1994). Presently, preclinical and clinical
protocols aim to increase the activity of 5-FU-based adjuvant
therapy. The optimal manner in which 5-FU should be
administered still remains to be determined. There appear to
be excellent reasons to start treatment immediately after
operation (Harris and Mastrangelo, 1991) and to administer
drugs intraperitoneally (Cunliffe and Sugarbaker, 1989).
Indeed, a survey of ongoing European trials shows
increasing interest in treatment modalities that include
immediate post-operative regional chemotherapy (Pahlman,
1995).
Much effort has also been directed at enhancing the
activity of 5-FU by drugs such as leucovorin and levamisole.
Recently, the potential of the interferons has been recognised
in this respect. Interferons are a family of multifunctional
proteins and components of the host defence against viral
and parasitic infections and malignancy (Sen and Lengyel,
1992). In vitro studies have demonstrated that each type of
interferon may interact with fluoropyrimidines in a synergistic
manner to produce cytotoxicity in a variety of human cancer
cell lines (see Grem et al., 1995). In phase II trials in patients
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with advanced colorectal carcinoma the combination of
interferon-a, plus or minus leucovorin, with 5-FU appears
to possess higher activity than 5-FU alone (Grem et al., 1991;
Pazdur, 1991; Wadler et al., 1991). This increased activity is
the result of biochemical modulation of 5-FU metabolism,
with both enhancement of the inhibition of thymidylate
synthase and alteration of the pharmacokinetics of 5-FU
being described.
Accepting the hypothesis that immediate post-operative
administration of interferon-a, together with 5-FU, might
benefit patients after resection of colorectal carcinoma, it
becomes essential to investigate the potential effects of these
drugs on early anastomotic healing in the intestine. Loss of
wound strength increases the risk for anastomotic dehiscence,
which is a most serious surgical complication with
concomitant high mortality and morbidity. Previous experi-
ments in our laboratory have shown that perioperative
intraperitoneal combination chemotherapy containing 5-FU
severely reduces early anastomotic strength (de Roy van
Zuidewijn et al., 1991). In addition, daily intraperitoneal 5-
FU alone from the day of operation onwards strongly
inhibits anastomotic repair in the rat intestine (Graf et al.,
1992; de Waard et al., 1995a). If administration of 5-FU
remains limited to the day of operation and the first two
post-operative days anastomotic strength is not significantly
affected (de Waard et al., 1993). In a recent experiment we
have examined the effects of 5-FU plus levamisole or
leucovorin on anastomotic healing (de Waard et al., 1995b).
Here, we describe our experiments into the effects of a 3 day
post-operative course of interferon-a and interferon-a plus 5-
FU on early healing of intestinal anastomoses in the rat.
Materials and methods
Animals
Altogether, 104 male outbred Wistar/Cpb:WU rats, weighing
between 200 and 300 g, were used. They were housed with
two animals per cage and had free access to water and
standard laboratory chow (diet AM II, Hope farms,
Woerden, The Netherlands).
For the measurement of anastomotic strength and
hydroxyproline content, 80 animals were randomly dividedFluorouracil, interferon and anastomotic healing
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into four groups of 20 animals each: a control group, a 5-FU
group, an interferon group and a group receiving 5-FU plus
interferon. Within each group, ten rats were killed at 3 and 7
days after operation. Collagen synthesis was measured in
similar groups of animals (n=6 each in each group). These
rats were killed 3 days after operation. The study was
approved by the Animal Ethics Review Committee of the
Faculty of Medicine, University of Nijmegen.
Drug administration
5-FU (Abic, Netanya, Israel) was given intraperitoneally in a
dose of 20 mg kg-' body weight (concentration: 1 mg ml-1
saline). This is the same dose we used before (de Waard et al.,
1993, 1995a,b) and represents the highest dose which, in
combination with surgery, did not result in a significant
mortality. Recombinant rat interferon-a (van der Meide et
al., 1986; specific activity 6 x 106 U mg-I protein) was
administered intraperitoneally in a dose of 2 x I04U kg-'
body weight (concentration: 2 x 103 U ml-1 saline). The drugs
were given once a day, on the day of operation and the next
2 days. The animals in the control groups received
intraperitoneal saline daily.
Operative procedure
After an intraperitoneal injection of sodium pentobarbital, a
midline incision was made and 1 cm of both small and large
bowel was resected, at 15 cm proximal to the ileocaecal
junction, and 3 cm proximal to the rectal peritoneal reflection
respectively. Continuity was restored microsurgically by the
construction of an inverted one-layer seromuscular end-to-
end anastomosis with eight interrupted sutures of 8 x 0
monofilament material (Ethicon, Sommerville, USA). The
abdomen was closed in two layers with a continuous 3 x 0
silk suture for the fascia and staples for the skin.
Analytical procedures
The rats were killed by an intraperitoneal overdose of sodium
pentobarbital. After opening the abdominal wound and
identifying the anastomoses, the adhesions were cut as far
as possible without injuring the intestine. An intestinal
segment with the anastomosis in the middle was removed,
with the sutures left in place. This segment was attached to
an infusion pump filled with methylene blue-stained saline.
The pressure was raised with an infusion rate of 4 ml min-'
and recorded graphically. Both the bursting pressure, i.e. the
maximum pressure recorded immediately before sudden loss
of pressure, and the site of rupture were noted. Thereafter,
the segment was placed in a tensiometer, and the breaking
strength was recorded. Thus, both the bursting pressure and
breaking strength were measured in the same anastomotic
segment. The validity of this procedure has been confirmed in
a pilot experiment. Anastomotic breaking strength was
compared in two groups of rats, either measured directly or
after the procedure used for measuring the bursting pressure,
and found to be similar in both groups (de Waard et al.,
1995b). The anastomotic segment was then cleaned from the
surrounding tissue and a 5 mm segment with the suture line
in the middle was collected. The samples were frozen
immediately and stored in liquid nitrogen until processing.
After weighing, the samples were pulverised and lyophilised
and the hydroxyproline content was measured as described
before (Hesp et al., 1984).
Collagen synthesis was analysed as the ex vivo collagen
synthetic capacity in intestinal explants by measuring the
incorporation of proline into collagenase-digestible protein
(CDP), according to a procedure validated before for rat
intestinal tissue (Martens etal., 1992). Briefly, tissue explants of
1-2 mm2, freshly collected from control segments removed at
operation and from anastomotic tissue removed 3 days after
operation, were incubated in medium containing [3H]proline
for 3 h and the radioactivity incorporated into total protein
was counted. Subsequently, in order to determine proline
incorporation into collagen, excess purified collagenase was
added. The radioactivity in the supernatant represents CDP, as
a measure of the amount of collagen synthesised. Subtraction
of the radioactivity in the CDP fraction from that in total
protein yields the incorporation into non-collagenous protein
(NCP). The relative collagen synthesis (RCS) was calculated
with the formula (Peterkofsky et al., 1981) that takes into
account the enrichment of proline in collagen compared with
other proteins:
Relative collagen synthesis (%) = (NCP x 5.4) + CDP x 100
Incorporation is expressed on the basis of sample wet weight,
DNA (Burton, 1956) content or protein (Smith et al., 1985)
content.
Statistical analysis
To correct for the fact that multiple comparisons were made,
pairwise comparisons of groups were performed (with a two-
tailed Mann-Whitney test) using a level of significance of
l= 2a/k, where k is the number of pairwise comparisons.
For instance, differences between the three experimental
groups and the control group (Figures 2-4) were considered
significant (a=0.05) at P<a1, where a&=2xO.05/3=0.033.
Results
No animalsdied prematurely duringtheexperimentalprotocol.
Up to 24 h after operation, all rats lost approximately 8% of
their body weight. Thereafter, animals regained weight,
although clear differences were observed between groups
(Figure 1). Weight gain in the 5-FU group was significantly
slower than in the control group. Administration of
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Figure 1 Course of body weight. Data represent mean values
(n =10) and, for the control group only, the s.d. (0), control
group; (S), interferon-a group; (A), 5-FU group; (A), 5-FU/
interferon-a group. Significant differences (P<0.033, see Materi-
als and methods) between groups are denoted by # (interferon-a
vs control group), * (5-FU vs control group) and $ (5-FU vs
5-FU/interferon-a group).
ninterferon-ax appeared to increase the rate of weight gain over
the first post-operative days: mean body weight was
significantly higher in the interferon-af group than in the
control group from day 3 onwards, and in the 5-FU/interferon-
a group than in the 5-FU group from day 5 onwards.
Anastomotic strength may be assessed both from the
bursting pressure, which represents its resistance to
intraluminal pressure, and from the breaking strength, which
reflects its ability to withstand longitudinal forces.
Figure 2 depicts the outcome of all measurements of
anastomotic bursting pressure performed at 3 days after
operation. At this time the bursting site was always within
the anastomotic area. In altogether six (out of 80)
anastomoses the bursting pressure could not be measured
because of technical problems. Neither 5-FU nor interferon-ax
administration led to a significant change in bursting
pressure. However, the mean bursting pressure of ileal
anastomoses in the 5-FU/interferon-a group (44+7 mmHg)
was significantly (P=0.0104) lower than that in the control
group (70+20 mmHg). In addition, it was also significantly
reduced with respect to the 5-FU group (P=0.0037) and the
interferon-a group (P=0.0062). In colon, these differences
did not reach statistical significance. At 7 days after
operation the bursting site was always outside the suture
line and therefore the bursting pressures measured (data not
shown) did not reflect actual wound strength.
When measuring the breaking strength (Figure 3) the
breaking site was invariably located within the wound area.
At 3 days after operation no differences were found between
groups, but after 7 days the breaking strength of both ileal
and colonic anastomoses was significantly lower in the 5-FU/
interferon-a group than in the control group. Also,
anastomotic breaking strength in the colon was reduced in
the interferon-a group.
The hydroxyproline content in 5 mm segments containing
the anastomosis was quantitated as a measure of wound
collagen levels (Figure 4). No differences between the control
group and the experimental groups were observed. The
hydroxyproline content increased similarly from 3 to 7 days
after operation independent of medication. Likewise, no
Fluorouracil, interferon and anastomotic healing
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differences were found for hydroxyproline concentrations.
Mean hydroxyproline concentrations were 7.0+1.3 and
9.6+1.8 ug mg-' dry weight in 3- and 7-day-old ileal
anastomoses respectively; corresponding values in colonic
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Figure 3 Anastomotic breaking strength. Bars represent mean
values (n=9 or 10)+s.d. 1, control group; 2, 5-FU group; 3,
interferon-a group; 4, 5-FU/interferon-a group. *Significantly
(P<0.033, see Materials and methods) different from control
group.
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Figure 2 Anastomotic bursting pressure after 3 days. Points
represent measurements in individual animals with bars indicating
mean values. *Significantly (P<0.033, see Materials and methods)
different from control group.
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Figure 4 Anastomotic hydroxyproline content. Bars represent
mean values (n = 1O)+ s.d. 1, control group; 2, 5-FU group; 3,
interferon-a group; 4, 5-FU/interferon-a group.
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anastomoses were 9.7+0.7 and 13.8+1.9 ig mg-1 dry
weight. Similar values were measured in the experimental
groups (data not shown).
The collagen synthetic capacity, measured ex vivo in tissue
explants, was assayed in control segments removed at
operation and in 3-day-old anastomotic tissue from the
same rats. Table I shows that in the control group collagen
synthetic capacity, expressed on the basis of DNA, wet
weight or protein, was strongly increased in wound tissue.
This increase was significantly (P=0.0313) higher in ileum
than in colon. The fact that the percentage relative collagen
synthesis was also elevated indicates that collagen synthesis
was stimulated to a larger extent than the synthesis of non-
collagenous proteins. Figure 5 depicts the anastomotic
collagen (and non-collagenous protein) synthetic capacity,
calculated on the basis of DNA content, for the various
groups. Treatment with 5-FU significantly reduced collagen
synthetic capacity without affecting the production of non-
collagenous protein. In contrast, treatment with interferon-a
did not appear to affect these processes to any substantial
degree since no significant differences were seen between the
interferon-a group and the control group or between the 5-
FU/interferon-a group and the 5-FU group. Similar results
were obtained if the collagen synthetic capacity was expressed
on the basis of wet weight or protein content (data not
shown).
Discussion
The continuing search for effective adjuvant therapy after
resection of colorectal carcinoma has resulted in a growing
interest in the efficacy of both immediate post-operative
regional chemotherapy (see Pahlman, 1995) and the
combination of 5-FU with interferon-a as the cytostatic
drugs of choice (see Grem et al., 1995). The present results
indicate that caution should be exerted in the use of
interferon-a as an adjunct to 5-FU therapy in the early
post-operative period since such treatment might constitute a
threat to undisturbed anastomotic healing. The combination
of interferon-a and 5-FU, administered intraperitoneally on
the day of operation and the first two post-operative days,
reduces the development of anastomotic strength during the
first week after its construction. Administration of 5-FU
alone has no significant deleterious effect on wound strength,
but interferon-a in itself significantly lowers strength below
control values in 7-day-old colonic anastomoses.
The wound healing process is characterised by massive cell
migration and proliferation. Cytostatic drugs are by nature
anti-proliferative and may therefore be expected to interfere
with wound healing. Indeed, 5-FU administered daily from
the day of operation onwards until sacrifice after 7 days
severely impairs anastomotic healing in the rat intestine (Graf
et al., 1992; de Waard et al., 1995b). In earlier experiments,
we tried to mitigate this negative effect by concomitant
administration of either interleukin 2 or granulocyte-
macrophage colony-stimulating factor, but 5-FU impaired
repair was not essentially altered by either cytokine. On the
other hand, retinol significantly promoted 5-FU suppressed
anastomotic healing (de Waard et al., 1995a). Also, we
reported before that the negative effect is limited if 5-FU is
given only three times (de Waard et al., 1993, 1995a). Since
we expected any additional effect of interferon-a to be
observed more easily under the latter conditions, we limited
drug administration to the first 3 days.
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Table I Increase in anastomotic collagen synthetic capacity 3 days
after operation
Control
segment Anastomosis Ratio
Ileum
D.p.m. jig1- DNA 41 ±6 194+30 4.9+ 1.2
D.p.m. mg-1 wet weight 85 ± 24 595 ± 72 7.6+ 2.2
D.p.m. mg-l protein 2578+ 654 14786±1953 6.0+ 1.4
RCS (%) 0.47+0.08 1.02+0.18 2.2+0.5
Colon
D.p.m. ,ug-1 DNA 86+ 18 221 +62 2.6+0.9
D.p.m. mg-1 wet weight 305 +45 773 + 150 2.6+0.7
D.p.m. mg-I protein 7317+ 1019 17454+3214 2.4+0.4
RCS (%) 1.12+0.12 1.72+0.32 1.5+0.2
Explants from control segments, collected at operation, and
anastomotic tissue, collected 3 days after operation, were incubated
for 3 h with 4.5 1iCi of[3H]proline. Collagen synthesis is expressed as
radioactivity in collagenase-digestible protein and as percentage
relative collagen synthesis (RCS). Data represent average values
(+s.d.) from six animals.
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Figure 5 Anastomotic collagen synthetic capacity. Bars represent
mean values (n =6) + s.d. of ex vivo synthesis of collagen (a,
expressed as radioactivity in collagenase-digestible protein; c,
expressed as percentage relative collagen synthesis, RCS) and
other proteins (b, expressed as radioactivity in non-collagenous
protein). 1, control group; 2, 5-FU group; 3, interferon-a group;
4, 5-FU/interferon-cx group. Differences between groups are
considered significant at P<0.017 (see Materials and methods)
and nearly significant (symbols in brackets) at P<0.033. *,
significant vs control group; $, significant vs 5-FU group; #,
significant vs interferon-a group.
1 TFk mi "toteoon and anast_moti heang
JWD de Waard et al
715
So far. little is clear about the effects of interferons on
wound healing. Interferon-;, delivered intraperitoneally
through an osmotic pump (Granstein et al., 1989) or injected
subcutaneously (Miles et al.. 1994). has been found to delay
skin repair in mice. In the latter study, wound disruption
strength was reduced significantly at a dose of 7 x IOW U kg-1
body weight and higher. Two experiments, with opposite
results, have been reported on the effects of interferon-xf# on
cutaneous healing in rodents. Intramuscular injection of
interferon-i fi or intraperitoneal administration of polyino-
sinic-polycytidylic acid, a potent inducer of interferon.
seemingly enhances repair (Bhartiya et al.. 1992). while local
subcutaneous injection of interferon-x f beneath the wound
actually inhibits repair (Stout et al., 1993). In these studies.
evaluation of repair was solely on the basis ofmacroscopic or
histological parameters; functional parameters. like wound
strength, were not reported.
The present study is the first effort to investigate the effect
of purified interferon-i on wound strength. Rat recombinant
interferon-i was given in a daily dose of 2 x I04 U kg-' body
weight. This dose is more than sufficient to protect rats
against a lethal pseudorabies vinus (PH van der Meide.
personal communication). but is substantially lower than the
doses of interferon employed in the studies mentioned above.
Still, daily doses of this relatively low dose of interferon-i.
administered on the first three post-operative days. signifi-
cantly reduce anastomotic breaking strength in the colon 7
days after operation. The results of treatment with the
combination of 5-FU and interferon-i are probably of more
immediate interest in terms of potential treatment of patients
with colorectal cancer. It seems clear that addition of
interferon-i to a regimen of 5-FU. which in itself does not
affect anastomotic strength, may lead to a significant and
substantial reduction in anastomotic strength during the first
week of healing. In this period, where clinically most leakages
occur, the strength of the anastomosed segment is relatively
low as compared with the strength of the uninjured intestine:
any further reduction constitutes a threat to anastomotic
integrity and increases the chances for anastomotic dehis-
cence. Thus, these data should be treated as a warning that
clinical application of 5-FU plus interferon-i immediately
after anastomotic construction, although possibly beneficial
with respect to adjuvant effectivity, may result in undesirable
(side-) effects with respect to wound repair.
It remains to be determined how exactly interferon-i
interferes with the healing sequence. The strength of both the
uninjured and the sutured bowel wall depends to a large
extent on collagen and anastomotic construction leads very
quickly to an increased collagen synthetic capacity within the
wound area (Martens and Hendriks, 1991). Interferons are
known to be able to inhibit collagen synthesis (Granstein et
al.. 1990). This suppressive effect is well established by in vitro
experiments with fibroblasts (Jimenez et al.. 1984: Duncan
and Berman. 1985). which are the primary producers of
extracellular matrix in the healing wound. Indeed. histologi-
cal examination of interferon--;-treated wounds indicates
reduced accumulation of collagen (Granstein et al.. 1989:
Miles et al.. 1994). However. our data show that treatment
with interferon-sx alone does not lead to lowering of either ex
vivo collagen synthetic capacity in anastomotic explants or
hydroxyproline accumulation in anastomotic segments. Such
an effect is indeed observed after 5-FU treatment, but again
addition of interferon-:x does not lead to further reduction.
This lack of effect of interferon-x may be explained by the
relatively low doses we used. Alternatively, it could be that
interferon-x has less effect on matrix production than the
other interferons. Experiments with isolated cells show this to
be true for fibroblast collagen synthesis, both on the protein
(Jimenez et al., 1984; Duncan and Berman. 1985) and the
mRNA level (Duncan et al.. 1995).
Anastomotic strength will also be affected by degradation
of the existing matrix anchoring the sutures. The methodol-
ogy used to measure the hydroxyproline content in
anastomotic segments. which necessarily contain uninjured
tissue next to the actual wound area, does not allow the
detection of very localised loss of collagen. It may be that
interferon-x increases collagenase expression (Duncan and
Berman, 1989: Hujanen et al.. 1994), although macrophage
metalloproteinase production appears to be inhibited by
interferon-; (Wahl and Corcoran. 1993).
Finally. one could speculate that interferon-x interferes
with healing by the inhibition of proliferation. either directly
or by biochemical modulation of 5-FU metabolism.
Interferons are growth inhibitors for a variety of normal
and transformed cell lines (see Mallat et al.. 1995). The
impairment of cutaneous healing by interferon-xz # is thought
to be caused primarily by inhibition ofproliferation of all cell
types involved in wound repair (Stout et al.. 1993). More
specifically, interferon-tx is known to inhibit endothelial cell
proliferation and thereby angiogenesis (Folkman. 1995).
processes inherent to successful repair.
Whatever the mechanism(s) responsible, our data clearly
indicate that administration of interferon-:x in the periopera-
tive period may be detrimental to anastomotic repair and
that its use in immediate post-operative adjuvant therapy. as
a means to enhance 5-FU activity, should be approached
with caution.
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